Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Suven Life Sciences Gains 7%; BSE HEALTHCARE Index Up 1.2%
Mon, 2 Dec 15:54

Suven Life Sciences Gains 7%; BSE HEALTHCARE Index Up 1.2%Image source: DNY59/www.istockphoto.com

Suven Life Sciences share price has zoomed 7% and is presently trading at Rs 138.7.

Meanwhile, the BSE HEALTHCARE index is at 44,196.0 (up 1.2%).

Among the top gainers in the BSE HEALTHCARE index today are MAX HEALTHCARE INSTITUTE (up 3.8%) and APOLLO HOSPITALS (up 3.3%).

Jubilant Pharmova (down 2.4%) and GSK Pharma (down 1.7%) are among the top losers today.

Over the last one year, Suven Life Sciences has moved up from Rs 84.3 to Rs 138.7, registering a gain of Rs 54.4 (up 64.6%).

On the other hand, the BSE HEALTHCARE index has moved up from 29,654.9 to 44,196.0, registering a gain of 49.0% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 178.5%), SUVEN PHARMACEUTICALS (up 103.6%) and Glenmark Pharma (up 101.2%).

End of Year Sale: Save Rs 6,050 on our small cap research

What About the Benchmark Indices?

The BSE Sensex is at 80,248.1 (up 0.6%).

The top gainers among the BSE Sensex today are Ultratech Cement (up 3.9%) and JSW Steel (up 2.5%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.

In the meantime, NSE Nifty is at 24,275.3 (up 0.6%). Ultratech Cement and APOLLO HOSPITALS are among the top gainers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 66,174.2 to 80,248.1, registering a gain of 14,073.9 points (up 21.3%).

Suven Life Sciences Financial Update...

Suven Life Sciences net profit fell 291.5% YoY to Rs -496 million for the quarter ended September 2024, compared to a loss of Rs 127 million a year ago. Net sales declined 15.9% to Rs 26 million during the period as against Rs 31 million in July-September 2023.

For the year ended March 2024, Suven Life Sciences reported 11.2% increase in net profit to Rs -1,051 million compared to net loss of Rs 1,183 million during FY23. Revenue of the company fell 13.6% to Rs 117 million during FY24.

The current Price to earnings ratio of Suven Life Sciences, based on rolling 12 month earnings, stands at -20.7.


Equitymaster requests your view! Post a comment on "Suven Life Sciences Gains 7%; BSE HEALTHCARE Index Up 1.2%". Click here!